01 Industry overview
The vo2 max testing industry at a glance
The global cardiopulmonary exercise testing market, the closest measurable proxy for VO₂ max testing, is estimated at $1.63 billion in 2026 and is forecast to reach $2.71 billion by 2031.
- $1.63B[4]
- Global market size, 2026
- 10.74%[4]
- Forecast CAGR, 2026–2031
- 38.46%[4]
- North America share, 2025
- 53.41%[4]
- Hospital end-user share, 2025
- Market size
- The global cardiopulmonary exercise testing market was valued at $1.47 billion in 2025 and is estimated at $1.63 billion in 2026. A narrower metabolic-testing-equipment definition places the 2025 market at $499.0 million, illustrating how results vary with the inclusion of clinical CPET systems and services.[4][5]
- Forecast & CAGR
- The global cardiopulmonary exercise testing market is projected to reach $2.71 billion by 2031, implying a 10.74% CAGR from 2026 to 2031. The narrower metabolic testing equipment market is forecast to grow from $533.9 million in 2026 to $981.6 million in 2035, at a 7.0% CAGR.[4][5]
- Market share & regions
- North America was the largest regional market in 2025, accounting for 38.46% of global cardiopulmonary exercise testing revenue. Asia-Pacific was identified as the fastest-growing region, with a forecast CAGR of 14.62% through 2031.[4]
- Segmentation
- CPET systems held 42.37% of product revenue in 2025, while clinical diagnostics represented 43.68% of application revenue. Hospitals accounted for 53.41% of end-user revenue, and cardiovascular diseases represented 34.52% of indication revenue.[4]
- Key players & concentration
- The market is characterized as having medium concentration. Reported leading manufacturers and brands include COSMED, Vyaire, MGC Diagnostics, CORTEX, Schiller, GE HealthCare, Philips and Nihon Kohden; a precise CR3, CR5 or HHI figure was not publicly disclosed in the available source.[4][6]
- Pricing
- In U.S. consumer and performance settings, a single VO₂ max test commonly costs about $100 to $250, depending on the facility and included analysis. UCSF lists its VO₂ max assessment at $299, while its test includes gas-exchange measurement and personalized training-zone information.[7][3]
- Trends, drivers & challenges
- Growth is being supported by demand for objective exercise-capacity assessment, cardiovascular and pulmonary disease management, pulmonary rehabilitation and sports-performance testing. Adoption remains constrained by equipment and service costs, specialist training requirements and inconsistent reimbursement; specialty cardiology and pulmonology clinics are forecast to grow at 13.28% annually through 2031.[4][8]
- Consumer behavior & competition
- The consumer market is expanding beyond hospitals into universities, performance centers, gyms and longevity providers, with tests sold directly for training-zone and fitness assessment purposes. Consumer-facing prices vary materially: Quest lists VO₂ max testing from $145, while UCSF lists a $299 assessment; smartwatch-based estimates compete with laboratory gas-analysis tests but do not provide the same direct measurement of oxygen uptake.[9][3]
- Regulation
- In the United States, clinical CPET is commonly billed under CPT 94621, which covers cardiopulmonary exercise testing with minute ventilation, carbon-dioxide production, oxygen uptake and electrocardiographic recordings. FDA-cleared metabolic systems include COSMED devices such as the K5 wearable metabolic technology, indicated for professional healthcare, rehabilitation and sports-medicine settings.[8][10]
- Latest news
- Recent market activity is centered on wider consumer access and portable testing rather than a single industry-defining transaction. In 2026, consumer providers were listing VO₂ max tests from $145 to $299, while market forecasts continued to identify portable and wearable metabolic systems as a growth area.[9][3][6]
02 Ranking
Top 10 Companies in the Vo2 Max Testing Industry
The leading companies in the vo2 max testing industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
COSMED stands out for VO2 max testing systems because it supplies Quark CPET, Q-NRG MAX and K5 systems for VO2 max testing, while PNOĒ focuses on lab-grade cardio-metabolic analyzers since it develops cardio-metabolic analyzers for VO2 max and metabolic testing.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in metabolic cart systems
COSMED
IT
Ranked #1 · 8.9 · Metabolic cart systems
Why we picked it: COSMED supplies Quark CPET, Q-NRG MAX and K5 systems for VO2 max testing.
#2 overall
PNOĒ
US
Ranked #2 · 8.8 · Metabolic cart systems
Why we picked it: PNOĒ develops lab-grade cardio-metabolic analyzers for VO2 max and metabolic testing.
#3 overall
MGC Diagnostics
US
Ranked #3 · 8.6 · Metabolic cart systems
Why we picked it: MGC Diagnostics develops metabolic testing systems under stress for cardiovascular and pulmonary performance.
Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | COSMED Metabolic cart systems · IT | 8.9 | 9.9 | 7.5 | 8.7 | 9.3 | |
Company snapshot · COSMED · Data as of November 20, 2026 COSMED supplies Quark CPET, Q-NRG MAX and K5 systems for VO2 max testing.[11]
| |||||||
| 2 | PNOĒ Metabolic cart systems · US | 8.8 | 7.0 | 9.9 | 9.9 | 9.9 | |
Company snapshot · PNOĒ · Data as of November 20, 2026 PNOĒ develops lab-grade cardio-metabolic analyzers for VO2 max and metabolic testing.[12]
| |||||||
| 3 | MGC Diagnostics Metabolic cart systems · US | 8.6 | 9.2 | 8.0 | 8.1 | 8.7 | |
Company snapshot · MGC Diagnostics · Data as of November 20, 2026 MGC Diagnostics develops metabolic testing systems for cardiovascular and pulmonary performance under stress.[13]
| |||||||
| 4 | Jaeger Medical Metabolic cart systems · DE | 8.5 | 9.2 | 7.5 | 8.1 | 8.7 | |
Company snapshot · Jaeger Medical · Data as of November 20, 2026 Jaeger Medical sells the Vyntus CPX metabolic cart for cardiopulmonary exercise testing.[14]
| |||||||
| 5 | CORTEX Biophysik Metabolic cart systems · DE | 8.2 | 7.5 | 8.0 | 8.7 | 9.3 | |
Company snapshot · CORTEX Biophysik · Data as of November 20, 2026 CORTEX describes itself as a world-market leader in mobile cardiopulmonary exercise testing.[15]
| |||||||
| 6 | VO2 Master Portable wearable VO2 analyzers · CA | 8.1 | 7.0 | 8.0 | 8.7 | 9.3 | |
Company snapshot · VO2 Master · Data as of November 20, 2026 VO2 Master sells a portable wireless analyzer for metabolic and VO2 analysis.[16]
| |||||||
| 7 | Parvo Medics Research and sports metabolic carts · US | 8.0 | 8.0 | 7.5 | 7.6 | 8.7 | |
Company snapshot · Parvo Medics · Data as of November 20, 2026 TrueOne 2400 measures maximal oxygen consumption and supports cardiopulmonary stress testing.[17]
| |||||||
| 8 | KORR Medical Technologies VO2 max systems for gyms and clinics · US | 7.9 | 8.0 | 7.5 | 7.6 | 8.2 | |
Company snapshot · KORR Medical Technologies · Data as of November 20, 2026 KORR's CardioCoach systems deliver VO2 max and sub-maximal oxygen-consumption testing.[7]
| |||||||
| 9 | Geratherm Medical Respiratory diagnostics and spiroergometry · DE | 7.6 | 7.4 | 7.3 | 7.9 | 8.2 | |
Company snapshot · Geratherm Medical · Data as of November 20, 2026 Geratherm Respiratory develops spiroergometry systems measuring oxygen uptake during exercise.[18]
| |||||||
| 10 | VacuMed Metabolic carts and VO2 measurement systems · US | 7.5 | 8.0 | 7.0 | 7.0 | 7.0 | |
Company snapshot · VacuMed · Data as of November 20, 2026 VacuMed sells Vista systems for resting metabolic rate and VO2 max measurements.[19]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 10 companies in the vo2 max testing industry. In Vo2 Max Testing Industry Statistics. Gitnux. https://gitnux.org/vo2-max-testing-industry-statistics/#top-companies
Global metabolism testing market share by product type
Metabolic Carts holds the largest share at 43%.
03 Trends & forecasts
Top 10 Vo2 Max Testing Industry Trends & Forecasts 2027
What is changing in the vo2 max testing industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01CPET demand accelerates through 2027
High confidenceThe global cardiopulmonary exercise testing market is estimated at $1.63 billion in 2026, up from $1.47 billion in 2025, and is forecast to reach $2.71 billion by 2031 at a 10.74% CAGR. This positions VO₂ max and CPET testing as a double-digit-growth diagnostic market rather than a mature niche.[4]
Forecast 2027: Market revenue should expand by roughly 10%–11% in 2027, supported by clinical diagnostics, rehabilitation and performance testing. Growth will remain strongest in systems and software that increase test throughput.
02Asia-Pacific outpaces mature regions
High confidenceNorth America accounted for 38.46% of global CPET revenue in 2025, while Asia-Pacific is forecast to grow at 14.62% annually through 2031. The gap indicates that North America remains the largest installed market, but Asia-Pacific is adding capacity faster.[4]
Forecast 2027: In 2027, suppliers should prioritize China, India and other Asia-Pacific markets through distributor networks, localized service and lower-cost configurations. Regional growth is likely to exceed the global average.
03Hospitals retain volume leadership
High confidenceHospitals represented 53.41% of CPET end-user revenue in 2025. CPET is used to assess exercise capacity, disease severity, prognosis and response to therapy across cardiovascular and pulmonary conditions.[4][20]
Forecast 2027: Hospitals will remain the largest buyer group in 2027, especially for integrated systems with ECG, gas exchange, ergometry and centralized reporting. Replacement purchases and tertiary-care referrals should support steady demand.
04Specialty clinics gain share
High confidenceSpecialty cardiology and pulmonology clinics are forecast to grow at 13.28% annually through 2031, faster than the overall market. Compact and semi-portable systems are making CPET more practical outside large hospital laboratories.[4]
Forecast 2027: In 2027, outpatient specialty clinics should be the fastest-growing clinical channel. Vendors will increasingly sell modular systems that can support spirometry, stress testing and full CPET from one platform.
05Pulmonary rehabilitation drives utilization
High confidencePulmonary rehabilitation is forecast to grow at 11.89% annually through 2031 and is identified as the fastest-growing CPET application. American Thoracic Society guidance describes rehabilitation as individually tailored exercise training with patient assessment and outcomes measurement.[4][21]
Forecast 2027: By 2027, CPET use should increase in pulmonary and cardiac rehabilitation pathways, particularly where clinicians need objective baselines and repeat measurements. Demand will favor systems with simple protocols and rapid comparison of longitudinal results.
06Metabolic carts grow faster than full systems
High confidenceCPET systems held 42.37% of product revenue in 2025, while metabolic carts are forecast to expand at an 11.34% CAGR through 2031. Cart-based configurations are attractive to outpatient, rehabilitation and performance facilities seeking lower installation complexity.[4]
Forecast 2027: Metabolic carts should gain modest share in 2027 as buyers choose flexible configurations over large fixed laboratories. Product differentiation will center on calibration time, portability, software and integration with ECG and blood-pressure modules.
07Portable testing expands beyond laboratories
High confidenceFDA-cleared COSMED K5 wearable metabolic technology measures oxygen uptake, carbon-dioxide production, ventilation, heart rate and energy expenditure for professional healthcare, rehabilitation and sports-medicine settings. COSMED also markets the Quark CPET as a gas-exchange system for exercise and resting protocols.[10][11]
Forecast 2027: Portable and wearable systems should see wider 2027 adoption in field testing, sports medicine, rehabilitation and multi-site services. They will complement rather than replace fixed clinical CPET systems because professional supervision and validation remain important.
08Consumer testing becomes more accessible
High confidenceConsumer-facing VO₂ max services are being sold through universities, hospitals, laboratories and fitness platforms. Current listed prices include $299 at UCSF, $175 for an initial UC Davis performance evaluation and $400 for a Fitnescity VO₂ max test listed through Quest.[3][22][23]
Forecast 2027: In 2027, direct-to-consumer testing should expand through gyms, performance centers, longevity providers and booking platforms. More providers will package the test with training zones, lactate testing, body composition or coaching.
09Prices remain highly segmented
High confidencePublished U.S. consumer prices range from $175 for an initial UC Davis VO₂ max evaluation to $299 at UCSF and $400 for a Quest-listed Fitnescity test. The spread reflects differences in facility type, interpretation, clinical oversight and bundled services.[22][3][23]
Forecast 2027: Prices should remain segmented in 2027 rather than converge. Entry-level testing will likely face pressure from gym and university providers, while hospital-grade assessments will preserve premium pricing through interpretation and medical supervision.
10Wearable estimates intensify competition
Medium confidenceSmartwatches and rings increasingly provide estimated VO₂ max or cardio-capacity metrics, while laboratory CPET directly measures oxygen uptake and carbon-dioxide output. Consumer technology coverage continues to distinguish wearable estimates from laboratory measurement.[3][24]
Forecast 2027: In 2027, wearables will compete mainly for frequent tracking and lead generation, not for replacement of diagnostic CPET. Testing providers will increasingly use lab results to validate, calibrate or explain wearable estimates.
04 Statistics
Pricing
Pricing stays segmented across public facilities and academic programs, with $165 per VO2max test in 2026 and $299 for a two-hour UCSF appointment.
Fees and price levels in the vo2 max testing industry
- $165 per VO2max test is listed by George Washington University’s Metabolism and Exercise Testing Laboratory Core for public testing in Washington, D.C., in 2026.[1]
- $360 per VO2max cardiorespiratory fitness test is listed in Mount Sinai Physiolab’s 2026 procedure rates for New York, United States.[2]
- $299 per VO2 max assessment is listed by the UCSF Human Performance Center for a two-hour appointment in San Francisco, California, in 2026.[3]
Key questions about the vo2 max testing industry
What is the 2026 market size for VO2 max testing using the CPET proxy?
How fast is the VO2 max testing proxy market expected to grow from 2026 to 2031?
Which companies lead the vo2 max testing industry?
What technology direction is showing up in 2026 market activity?
How is the market structured by end user and product in 2025?
What does U.S. clinical CPET billing cover under CPT 94621?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Vo2 Max Testing Industry Statistics. Gitnux. https://gitnux.org/vo2-max-testing-industry-statistics
Samuel Norberg. "Vo2 Max Testing Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/vo2-max-testing-industry-statistics.
Samuel Norberg. 2026. "Vo2 Max Testing Industry Statistics." Gitnux. https://gitnux.org/vo2-max-testing-industry-statistics.
Sources & references
24 sources cited across this report
bodycomposition.gwu.edu
mountsinai.org
hpc.ucsf.edu
mordorintelligence.com
emergenresearch.com
reportprime.com
korr.com
cms.gov
- mitohealth.com
accessdata.fda.gov
cosmed.com
pnoe.com
mgcdiagnostics.com
- jaegerrdx.com
cortex-medical.com
vo2master.com
- parvo.com
geratherm.com
- vacumed.com
evidence.nejm.org
pmc.ncbi.nlm.nih.gov
health.ucdavis.edu
questhealth.com
t3.com
